

and would place restrictions on Federal credit union involvement in repurchase and reverse repurchase agreements.

The preamble to the proposed regulation cautioned Federal credit unions to refrain from engaging in the activities described in the body of the regulation and that advice continues to apply. Although the cautionary note does not prohibit those investment activities pending final rulemaking, it does serve as notice to Federal credit unions to exercise due care in making investments. Failure to exercise sound business judgment regarding investments will be considered as an unsafe and unsound practice in conducting credit union business.

Several parties have already requested additional time to review the proposed regulation and submit comments. Due to the complexity of investment transactions and market operations, and the fact that transactions involving government securities is currently highly controversial, and because the proposed rule would impact on Federal credit union investment practices in an area not previously regulated, the National Credit Union Administration has determined that an additional opportunity for interested parties to submit comments is appropriate and in the public interest. Therefore, the comment period, originally set to expire on December 15, 1978, is hereby extended to March 15, 1979.

(Sec. 107, 91 Stat. 49 (12 U.S.C. 1757), sec. 120, 73 Stat. 635 (12 U.S.C. 1766) and sec. 209, 84 Stat. 1104 (12 U.S.C. 1789))

LAWRENCE CONNELL,
Administrator.

DECEMBER 5, 1978.

[FR Doc. 78-34537 Filed 12-11-78; 8:45 am]

[1505-01-M]

**DEPARTMENT OF HEALTH,
EDUCATION, AND WELFARE**

Food and Drug Administration

[21 CFR Part 344]

[Docket No. 77N-0334]

OVER-THE-COUNTER DRUGS

**Establishment of a Monograph for OTC Topical
Otics; Corrections**

In FR Doc. 77-35320 appearing at page 63566 in the issue for Friday, December 16, 1977, make the following corrections:

1. On page 63558, second column, next to the last line of the paragraph, "tropical" should read "topical"; and the paragraph numbered "2. *Cerumen*". should read "a. *Cerumen*".

2. On page 63560, first column, in the table, in the heading, "Oct" should read "OTC"; and entries numbered 5 and 6, the second column entry of the table for each should read: "No topical otics."

3. On page 63561, third column, last line of Reference 26, "85" should read "84".

4. On page 63564, third column, second paragraph under b., next to the last line, "anestic" should read "anesthetic".

5. On page 63566, first column, last line of (a) under § 344.50, insert "wax" before "softening".

[1505-01-M]

[21 CFR Part 352]

[Docket No. 78N-00338]

SUNSCREEN DRUG PRODUCTS FOR OVER-THE-COUNTER HUMAN USE

**Establishment of a Monograph; Notice of
Proposed Rulemaking**

Corrections

In FR Doc. 78-22963 appearing at page 38206 in the issue for Friday, August 25, 1978, make the following corrections:

1. On page 38206, third column, third line of the paragraph numbered 3, "date" should read "data".

2. On page 38207, second column, the first full paragraph should read as follows:

"The following FDA employees served: C. Carnot Evans, M.D., served as Executive Secretary. Lee Geismar served as Panel Administrator. Lee Quon, R.Ph., served as Drug Information Analyst until July, 1973, followed by Thomas H. Gingrich, R.Ph., until July, 1975, followed by Timothy T. Clark, R.Ph., until July, 1976, followed by Victor H. Lindmark, Pharm. D."

2A. On page 38208, second column, fourth line under 1. *Active ingredients*, "Cinoxate" should be listed as a separate item.

2B. On page 38209, third column, ninth line, delete the hyphen between "Ninety-five" and insert instead: "to ninety".

3. On page 38207, second column, twelfth line of the second paragraph, "Maiback" should read "Maibach".

4. On page 38220, second column, first line of the first full paragraph, "dutaneous" should read "cutaneous"; and in the second paragraph, fifth line, insert "120," after "60,".

5. On page 38230, first column, second paragraph, twenty-second line, "to" should read "a".

6. On page 38244, first column, last line of the first full paragraph, "bly-

cerin" should read "glycerin"; second column, second paragraph, second line, "which" should read "white".

7. On page 38245, first column, eleventh line of the paragraph at the bottom, "dioxoybenzone" should read "dioxybenzone"; and in the second paragraph, twenty-second line from the top of the second column, "dioxoybenzone" should read "dioxybenzone".

8. On page 38246, first column, last line of Reference 8 should read: "060135".

9. On page 38248, first column, fourth line of first full paragraph, "seat" should read "sweat".

10. On page 38252, third column, twelfth line from the bottom, insert the following after "ema": "to 5 (peeling). The treated sites showed no evidence of erythema * * *".

11. On page 38254, third column:
(a) First paragraph lettered a., fifth line, insert a hyphen after "2";

(b) Second paragraph under a., second line, insert a hyphen after "2";

(c) Paragraph numbered (1), fourth line, insert a hyphen after "2"; and
(d) Fifth paragraph, third line, insert a hyphen after "2".

12. On page 38256, second column, first line insert ")" after " * * * norbornyliden".

13. On page 38260, first column, fifth paragraph, seventh line should read: " λ_H (50 per cent transmittance point"; and in the first line of the last paragraph, "Regardless" should read "Regardless".

14. On page 38264, first line of (a)(1) of § 352.3, "Minimal" should read "Minimal".

[6735-01-M]

**FEDERAL MINE SAFETY AND HEALTH
REVIEW COMMISSION**

[29 CFR Part 2700]

PROCEDURAL RULES

**Extension of Comment Period on Proposed
Rules of Procedure**

AGENCY: Federal Mine Safety and Health Review Commission.

ACTION: Extension of comment period on proposed rules of procedure

SUMMARY: On October 21, 1978, the Federal Mine Safety and Health Review Commission proposed the amendment of its rules of procedure. The Commission invited the comments of interested persons and permitted the filing of written views and data until November 30, 1978. 43 FR 50712. On November 15, 1978, the Commission announced that a public hearing on its proposal would be held on December 5, 1978. 43 FR 53045. On